Provisional guidance on the role of specific antibiotics in the management of Mycobacterium ulcerans disease (Buruli ulcer)

Overview

! WARNING!
ARCHIVED PUBLICATION

This publication contains guidance that is out of date. Please refer to : Updated document

Recent research and clinical experience have shown that a combination of rifampicin and an aminoglycoside (streptomycin or amikacin1) given for 4–12 weeks with or without surgery is promising in the management of Mycobacterium ulcerans disease (Buruli ulcer). While the medical community awaits the results of further drug treatment trials, current and future patients may benefit from the knowledge gained to date.

This document is based on available information and expert opinion, to help health workers in affected areas to better manage patients with M. ulcerans disease. The implementation of this guidance will require considerable clinical judgement and close monitoring of patients to ensure the best possible treatment outcome.